293 related articles for article (PubMed ID: 12793386)
1. FDA begins product approval initiative.
Lewis C
FDA Consum; 2003; 37(3):10-1. PubMed ID: 12793386
[No Abstract] [Full Text] [Related]
2. FDA plan for statutory compliance. Notice of availability.
Fed Regist; 1998 Nov; 63(226):65000-40. PubMed ID: 10338873
[TBL] [Abstract][Full Text] [Related]
3. Advisory committees" critical to the FDA's product review process.
Rados C
FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
[No Abstract] [Full Text] [Related]
4. FDA science: from concept to consumer.
Rados C
FDA Consum; 2004; 38(3):10-1. PubMed ID: 15218837
[No Abstract] [Full Text] [Related]
5. Significant FDA approvals in 2000.
McGinnis TJ
Am Fam Physician; 2001 May; 63(10):2061-4. PubMed ID: 11388719
[No Abstract] [Full Text] [Related]
6. Of specialty interest: the Food and Drug Administration: a partner in safe practice.
Baker K
ORL Head Neck Nurs; 2003; 21(2):25-7. PubMed ID: 12747041
[TBL] [Abstract][Full Text] [Related]
7. Significant FDA approvals in 2001.
McGinnis TJ
Am Fam Physician; 2002 Jun; 65(11):2377-8, 2380, 2383. PubMed ID: 12074535
[No Abstract] [Full Text] [Related]
8. Remarks of the Commissioner of Food and Drugs.
Henney JE
Food Drug Law J; 2000; 55(1):1-4. PubMed ID: 12269355
[No Abstract] [Full Text] [Related]
9. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
Burkhart CG
J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
[No Abstract] [Full Text] [Related]
10. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
Lang L
Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
[No Abstract] [Full Text] [Related]
11. Making medical progress. A look at FDA approvals in 2000.
FDA Consum; 2001; 35(2):7-8. PubMed ID: 11444251
[No Abstract] [Full Text] [Related]
12. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
13. Working together to enhance the efficiency of medical product development.
Sanhai WR
J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
[No Abstract] [Full Text] [Related]
14. Teaching the elephant to dance: privatizing the FDA review process.
Price EC
Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
[No Abstract] [Full Text] [Related]
15. Change, but not in dollar bills. FDA needs more than money to fix problems: Congress.
Lubell J
Mod Healthc; 2008 Feb; 38(5):10-1. PubMed ID: 18320666
[No Abstract] [Full Text] [Related]
16. The year in review. A panoply of product approvals.
Nordenberg T
FDA Consum; 2000; 34(3):10-2. PubMed ID: 11521248
[No Abstract] [Full Text] [Related]
17. Regulatory watch: FDA PDUFA goals missed.
Hay M
Nat Rev Drug Discov; 2009 Jan; 8(1):10. PubMed ID: 19116619
[No Abstract] [Full Text] [Related]
18. Pessimistic response to FDA leadership change.
Kling J
Nat Biotechnol; 2005 Nov; 23(11):1325. PubMed ID: 16273044
[No Abstract] [Full Text] [Related]
19. The Center for Devices and Radiological health: an update.
Donawa M
Med Device Technol; 2001 Dec; 12(10):24, 26-7. PubMed ID: 15966141
[TBL] [Abstract][Full Text] [Related]
20. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
